clofilium and pazopanib

clofilium has been researched along with pazopanib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Andrianteranagna, M; Anthony, E; Aynaud, MM; Baulande, S; Bohec, M; Bourdeaut, F; Cairo, S; Chauvin, C; Del Nery, E; Delattre, O; Han, ZY; Leruste, A; Lescure, A; Maillot, L; Masliah-Planchon, J; Richer, W; Roman-Roman, S; Surdez, D; Tauziede-Espariat, A; Zaidi, S	1

Other Studies

1 other study(ies) available for clofilium and pazopanib

Article	Year
High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors. Cell reports, 2017, Nov-14, Volume: 21, Issue:7 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Discovery; Endoplasmic Reticulum Stress; High-Throughput Screening Assays; Humans; Indazoles; Protein Kinase Inhibitors; Pyrimidines; Quaternary Ammonium Compounds; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Rhabdoid Tumor; SMARCB1 Protein; Sulfonamides	2017

Article

Year

High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors.

Cell reports, 2017, Nov-14, Volume: 21, Issue:7

Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Discovery; Endoplasmic Reticulum Stress; High-Throughput Screening Assays; Humans; Indazoles; Protein Kinase Inhibitors; Pyrimidines; Quaternary Ammonium Compounds; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Rhabdoid Tumor; SMARCB1 Protein; Sulfonamides

2017